438 related articles for article (PubMed ID: 10599706)
1. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
[TBL] [Abstract][Full Text] [Related]
2. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
Poomthavorn P; Suphasit R; Mahachoklertwattana P
Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
[TBL] [Abstract][Full Text] [Related]
3. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
[TBL] [Abstract][Full Text] [Related]
4. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
Pasquino AM; Municchi G; Pucarelli I; Segni M; Mancini MA; Troiani S
J Clin Endocrinol Metab; 1996 Mar; 81(3):948-51. PubMed ID: 8772556
[TBL] [Abstract][Full Text] [Related]
6. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment.
Sørensen K; Andersson AM; Skakkebaek NE; Juul A
J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314
[TBL] [Abstract][Full Text] [Related]
7. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
8. Influence of GnRH analog therapy on body mass in central precocious puberty.
Głab E; Barg E; Wikiera B; Grabowski M; Noczyńska A
Pediatr Endocrinol Diabetes Metab; 2009; 15(1):7-11. PubMed ID: 19454183
[TBL] [Abstract][Full Text] [Related]
9. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
10. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty.
Paterson WF; McNeill E; Young D; Donaldson MD
Clin Endocrinol (Oxf); 2004 Nov; 61(5):626-34. PubMed ID: 15521967
[TBL] [Abstract][Full Text] [Related]
11. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
[TBL] [Abstract][Full Text] [Related]
13. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty.
Weise M; Flor A; Barnes KM; Cutler GB; Baron J
J Clin Endocrinol Metab; 2004 Jan; 89(1):103-7. PubMed ID: 14715835
[TBL] [Abstract][Full Text] [Related]
14. Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist.
Ko JH; Lee HS; Lim JS; Kim SM; Hwang JS
Horm Res Paediatr; 2011; 75(3):174-9. PubMed ID: 20881364
[TBL] [Abstract][Full Text] [Related]
15. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L
J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
[TBL] [Abstract][Full Text] [Related]
16. [Impact of gonadotropin-releasing hormone analogs on body mass index in girls with idiopathic central precocious puberty: a long-term follow-up study].
Yuan JN; Liang L; Cai XD; Li Z; Bai M; Gu CP
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):896-9. PubMed ID: 22099200
[TBL] [Abstract][Full Text] [Related]
17. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height.
Chiocca E; Dati E; Baroncelli GI; Mora S; Parrini D; Erba P; Bertelloni S
Neuroendocrinology; 2009; 89(4):441-7. PubMed ID: 19176945
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
Heger S; Partsch CJ; Sippell WG
J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
[TBL] [Abstract][Full Text] [Related]
19. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents.
Iannetta R; Melo AS; Iannetta O; Marchini JS; Paula FJ; Martinelli CE; Rosa e Silva AC; Ferriani RA; Martins WP; Reis RM
J Pediatr Adolesc Gynecol; 2015 Oct; 28(5):304-8. PubMed ID: 26081481
[TBL] [Abstract][Full Text] [Related]
20. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children.
Wolters B; Lass N; Reinehr T
Horm Res Paediatr; 2012; 78(5-6):304-11. PubMed ID: 23257624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
